Stanley Laman Group Ltd. Sells 14,925 Shares of UiPath Inc. (NYSE:PATH)

Stanley Laman Group Ltd. trimmed its stake in UiPath Inc. (NYSE:PATH) by 4.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 335,462 shares of the healthcare company’s stock after selling 14,925 shares during the period. UiPath accounts for about 1.3% of Stanley Laman Group Ltd.’s investment portfolio, making the stock its 13th largest position. Stanley Laman Group Ltd. owned approximately 0.06% of UiPath worth $8,333,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the stock. HighMark Wealth Management LLC bought a new position in UiPath in the 4th quarter worth approximately $27,000. Fifth Third Bancorp increased its position in UiPath by 2,005.3% in the 3rd quarter. Fifth Third Bancorp now owns 2,000 shares of the healthcare company’s stock worth $34,000 after buying an additional 1,905 shares during the period. GAMMA Investing LLC bought a new position in UiPath in the 4th quarter worth approximately $36,000. FNY Investment Advisers LLC bought a new position in UiPath in the 4th quarter worth approximately $40,000. Finally, FSC Wealth Advisors LLC bought a new position in UiPath in the 4th quarter worth approximately $43,000. 62.50% of the stock is owned by institutional investors.

UiPath Trading Down 1.4 %

Shares of NYSE PATH traded down $0.29 during mid-day trading on Thursday, reaching $19.42. 5,227,271 shares of the company’s stock were exchanged, compared to its average volume of 8,752,624. The firm has a market capitalization of $11.05 billion, a price-to-earnings ratio of -114.20 and a beta of 0.96. The business has a fifty day simple moving average of $22.30 and a 200 day simple moving average of $21.53. UiPath Inc. has a twelve month low of $12.38 and a twelve month high of $27.87.

UiPath (NYSE:PATH) last posted its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.10. The business had revenue of $405.25 million during the quarter, compared to the consensus estimate of $383.32 million. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. Equities research analysts predict that UiPath Inc. will post -0.04 earnings per share for the current fiscal year.

Insider Buying and Selling at UiPath

In other news, CFO Ashim Gupta sold 40,000 shares of UiPath stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $21.66, for a total transaction of $866,400.00. Following the completion of the transaction, the chief financial officer now directly owns 660,762 shares in the company, valued at approximately $14,312,104.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 72,000 shares of company stock worth $1,591,360 over the last ninety days. 31.03% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

PATH has been the topic of several recent analyst reports. Evercore ISI lifted their price target on UiPath from $24.00 to $27.00 and gave the stock an “in-line” rating in a research report on Thursday, March 14th. TD Cowen boosted their price objective on UiPath from $25.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, March 14th. William Blair initiated coverage on UiPath in a research note on Tuesday, January 2nd. They issued an “outperform” rating for the company. Mizuho upped their target price on UiPath from $22.00 to $25.00 and gave the company a “neutral” rating in a research note on Thursday, March 14th. Finally, JPMorgan Chase & Co. upgraded UiPath from a “neutral” rating to an “overweight” rating and upped their target price for the company from $22.00 to $28.00 in a research note on Thursday, March 14th. Nine analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, UiPath presently has a consensus rating of “Moderate Buy” and an average target price of $27.41.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.